Brain Health - Lifespan Edge

Category: Brain Health

Brain Health Research

Therapeutic Plasma Exchange as a Tool for Reversing Age-Related System Dysfunction With A Special Emphasis On Reversing Brain Dysfunction

/ by Mae Savick

By Patrick Cox, Research Analyst, Lifespan Edge  Brief Foreword  By Dr. Michael Roizen and John Mauldin, Co-Founders, Lifespan Edge   This brief paper by Patrick Cox does the important job of summarizing thousands of pages of significant research introducing the benefits of Therapeutic Plasma Exchange (TPE). It does so by outlining the history of the […]

Read more

Brain Health Research

AMBAR (Alzheimer Management by Albumin Replacement) Study

/ by Unmesh deolekar

The AMBAR (Alzheimer Management by Albumin Replacement) study explored a unique treatment approach that involves removing and replacing a portion of a person’s blood plasma—known as plasma exchange—to see if it might help slow the progression of Alzheimer’s disease. Researchers tested this procedure in people with mild-to-moderate Alzheimer’s, aiming to filter out and replace specific […]

Read more

Brain Health Research

Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild‑to‑moderate Alzheimer’s disease: additional results from the AMBAR study

/ by Unmesh deolekar | Leave a Comment

This study, part of the AMBAR phase 2b/3 clinical trial, investigated the effects of therapeutic plasma exchange (PE) with albumin replacement on brain structure and function in patients with mild-to-moderate Alzheimer’s disease (AD). Patients were divided into four groups: three received PE with varying doses of albumin (some with intravenous immunoglobulin, IVIG), while the fourth […]

Read more

Brain Health Research

Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin

/ by Unmesh deolekar | Leave a Comment

This phase 2b/3 trial evaluated the effects of plasma exchange (PE) with albumin replacement on patients with mild-to-moderate Alzheimer’s disease (AD). A total of 347 patients were randomized into three This study challenges the idea that young blood is necessary for tissue rejuvenation, showing instead that “neutral blood exchange” (NBE) — replacing half of an […]

Read more

Brain Health Research

A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease: Primary results of the AMBAR Study

/ by Unmesh deolekar | Leave a Comment

This phase 2b/3 trial evaluated the effects of plasma exchange (PE) with albumin replacement on patients with mild-to-moderate Alzheimer’s disease (AD). A total of 347 patients were randomized into three treatment groups with varying doses of albumin and intravenous immunoglobulin (IVIG) or a placebo group. The treatment included an initial 6-week period of weekly PE, […]

Read more

Brain Health Research

Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer’s Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial

/ by Unmesh deolekar | Leave a Comment

This study examined whether plasma exchange (PE) with albumin replacement could alter amyloid-β (Aβ) levels in cerebrospinal fluid (CSF) and plasma and improve cognitive function in patients with mild-to-moderate Alzheimer’s disease (AD). In this phase II trial, 42 AD patients were assigned to either PE treatment or a control group. Treated patients received up to […]

Read more

Brain Health Research

Plasma dilution improves cognition and attenuates neuroinflammation in old mice

/ by Unmesh deolekar | Leave a Comment

This study reveals that “neutral blood exchange” (NBE)—a procedure that dilutes old blood plasma without adding young blood factors—can rejuvenate tissues and improve brain function in aged mice. Unlike young blood infusions, NBE resets the body’s signaling environment, enhancing muscle and liver repair, hippocampal neurogenesis, and cognitive performance in older mice. Key findings include: These […]

Read more

Brain Health Research

Complementary analyses of the AMBAR trial: Impact of discontinuations, consistency of results across outcomes and additional adjustments

/ by Unmesh deolekar | Leave a Comment

The AMBAR study analyzed the effects of plasma exchange (PE) with albumin (with or without intravenous immunoglobulin, IVIG) on mild-to-moderate Alzheimer’s disease (AD) patients. Of the 496 patients enrolled, 347 were randomized into three treatment groups (different doses of albumin and IVIG) and a placebo group. Results showed that PE slowed cognitive and functional decline […]

Read more

Brain Health Research

Plasma Replacement Shows Success in Mild to Moderate Alzheimer Disease

/ by Unmesh deolekar | Leave a Comment

The AMBAR (Alzheimer Management by Albumin Replacement) study by Grifols demonstrated that plasma exchange (PE) with albumin and immunoglobulin replacement could delay cognitive and functional decline in patients with mild-to-moderate Alzheimer’s disease (AD). Over a 14-month period, 347 patients received PE treatment, which involved six weeks of weekly PE sessions followed by 12 months of […]

Read more

Brain Health Research

Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer’s disease?

/ by Unmesh deolekar | Leave a Comment

Therapeutic plasma exchange (TPE) is being explored as a treatment for Alzheimer’s disease (AD) to remove toxic or aging-related factors from the blood. Preclinical studies showed that injecting plasma from young mice into AD mice improved cognitive function, even though it did not reduce brain amyloid plaques. Early clinical trials, including a small study with […]

Read more

Brain Health Research

Emerging insights into the role of albumin with plasma exchange in Alzheimer’s disease management

/ by Unmesh deolekar | Leave a Comment

Alzheimer’s disease (AD) is a neurodegenerative condition marked by cognitive decline and eventually death. The main pathological features of AD include amyloid-β (Aβ) plaques and neurofibrillary tangles, but oxidative stress and inflammation are also major contributors to AD progression. Current pharmacologic treatments only address symptoms, and many trials targeting amyloid and non-amyloid pathways have failed. […]

Read more

Brain Health Research

Longitudinal lipidomic analyses in patients undergoing therapeutic plasma exchange with albumin replacement as a treatment for Alzheimer’s disease

/ by Unmesh deolekar | Leave a Comment

This study from the AMBAR trial investigated the effects of plasma exchange with albumin replacement (PE-Alb) on lipidomic profiles in patients with mild-to-moderate Alzheimer’s disease (AD). Since lipid differences are known between AD patients and healthy individuals, this study aimed to see if PE-Alb could impact lipid biomarkers associated with AD. Methodology: Key Findings: Conclusion: […]

Read more

To top